10 Oct 2025
On Monday, Mirxes announced a strategic joint venture (JV) with Xeraya Opportunities Fund PCC to establish MYRNA Diagnostics. Under the terms of agreement, Mirxes and Xeraya will contribute US$2 million and US$3 million, respectively, aligned with their equity stakes of 40% (Mirxes) and 60% (Xeraya).
CROSBY Research – Mirxes Holding (2629 HK/NR): Marking a pivotal step in regional expansion through JV